FULC Q4 2024 Earnings — Fulcrum Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FULCFulcrum Therapeutics, Inc.

$436M

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

-$369,000

Operating Income

-$19M

Net Income

-$17M

EPS (Diluted)

$-0.31

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$17M

Free Cash Flow

-$17M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$261M

Total Liabilities

$18M

Stockholders' Equity

$243M

Cash & Equivalents

$58M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$871,000	-100.0%
Gross Profit	-$369,000	$363,000	-201.7%
Operating Income	-$19M	-$28M	+30.6%
Net Income	-$17M	-$25M	+33.1%